<DOC>
	<DOCNO>NCT02313584</DOCNO>
	<brief_summary>The purpose study investigate appropriate duration dabigatran use radiofrequency catheter ablation paroxysmal atrial fibrillation patient low thromboembolic risk . According recent guideline , anticoagulation recommend continue least 2 month procedure . However bleed risk anticoagulant also problematic . Post-procedural thrombosis consider due acute inflammation char formation site ablation , reaction occur mostly within 1 month procedure . Also , risk thromboembolism low patient CHA2DS2-VASc score less 1 . The investigator hypothesize dabigatran use first 1 month RFCA patient paroxysmal AF low thromboembolic risk would sufficient efficacy safety compare conventional dabigatran use 2 month .</brief_summary>
	<brief_title>Investigation Appropriate Duration Dabigatran Use After Catheter Ablation Paroxysmal Atrial Fibrillation Patients With Low Thromboembolic Risk</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>paroxysmal AF undergoing catheter ablation CHA2DS2VASc score &lt; = 1 informed consent persistent AF CHA2DS2VASc score &gt; 2 prior CVA prior atnicoagulant severe HF abnormal liver renal function history severe bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>dabigatran</keyword>
</DOC>